Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Recruiting now

Conditions studied: Alopecia Areata, Janus Kinase Inhibitors

In brief

The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.

Key facts

Study ID

NCT06573593

Run by

Second Affiliated Hospital, Zhejiang University, School of Medicine

People needed

150

Starts

2024-07-29

Expected to finish

2026-12-31

Last updated by the study team

2024-08-27

Who can join

Age: 2 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with alopecia areata between 2 to 18 years old
• Patients diagnosed with alopecia areata according to AA guideline
• AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months

You may not qualify if…

• Patients had previously received hair implants
• Other alopecia
• Other diseases may induce alopecia including psoriasis, lichen planus, et al.
• Unable to estimate SALT score at baseline or at follow-up
• Patients are participating in other clinical trials

Where it is running

• Second Affiliated Hospital, School of Medicine, Zhejiang University, China — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.